NEURONTIN
Drug
UPJOHN US 1 LLC
Total Payments
$4.2M
Transactions
94
Doctors
2
Companies
3
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2023 | $295.00 | 1 | 0 |
| 2022 | $100,608 | 14 | 0 |
| 2021 | $4.1M | 77 | 0 |
| 2018 | $9,004 | 2 | 2 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $4.2M | 92 | 99.8% |
| Consulting Fee | $9,000 | 1 | 0.2% |
| Education | $4.47 | 1 | 0.0% |
Payments by Type
Research
$4.2M
92 transactions
General
$9,004
2 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A9451180 STUDY NAME NOT AVAILABLE YET | UPJOHN US 1 LLC | $4.2M | 0 |
| Evaluating the Abuse Potential of NEURONTIN When Taken Orally in Healthy Non-drug Dependent Participants With Sedative Drug Abuse Experience - A9451180 | Mylan Inc. | $295.00 | 0 |
Ad
Manufacturing Companies
- UPJOHN US 1 LLC $4.2M
- PFIZER INC. $9,004
- Mylan Inc. $295.00
Product Information
- Type Drug
- Total Payments $4.2M
- Total Doctors 2
- Transactions 94
About NEURONTIN
NEURONTIN is a drug associated with $4.2M in payments to 2 healthcare providers, recorded across 94 transactions in the CMS Open Payments database. The primary manufacturer is UPJOHN US 1 LLC.
Payment data is available from 2018 to 2023. In 2023, $295.00 was paid across 1 transactions to 0 doctors.
The most common payment nature for NEURONTIN is "Unspecified" ($4.2M, 99.8% of total).
NEURONTIN is associated with 2 research studies, including "A9451180 STUDY NAME NOT AVAILABLE YET" ($4.2M).